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Background.– This study assessed the efficacy of Abobotulinumtoxin A
(Dysport®) on upper limb spasticity (ULS) and function in hemiparetic adults
following stroke/traumatic brain injury.
Methods.– Phase III, prospective, double-blind, placebo-controlled study; 243
patients (from 34 sites in 9 countries) were randomized (1:1:1) to Dysport® 500
or 1000 units (U) or placebo.
Primary objective.– To assess the efficacy of Dysport® in reducing upper limb
muscle tone (using MAS) in patients’ primary targeted muscle group (finger,
wrist or elbow flexors). Secondary objectives.– Clinical benefit, assessed by
Physician Global Assessment (PGA), and improvement in passive function,
assessed by the Disability Assessment Scale (DAS).
Results.– A significantly higher proportion of patients compared to placebo were
responders:
– ≥ 1 point improvement in MAS as early as 1 week and 4 and 12 weeks post-
injection with either dose of Dysport®;
– significant clinical benefit, according to PGA scale, was also observed.
Similarly, a significantly higher proportion of patients demonstrated ≥ 1 grade
improvement in DAS at week 4 and 12 with 1000 U. No new safety events were
observed.
Conclusions.– Dysport® 500 and 1000 U improved muscle tone and function,
and provided clinical benefit in adults with ULS. Safety profile was consistent
with the known profile of Dysport® in this indication.
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Background.– Botulinum neurotoxin A manages spasticity disorders in neuro-
logical central diseases. But this treatment may induce muscular modifications.
Methods.– We made a literature review in order to explore the structural and
passive biomechanical properties of the musculotendinous unit after injections
in healthy animal muscles and in spastic human muscles, as well as the methods
of evaluation of theses properties.
Results.– Twenty articles have been selected. Histological analyses have
been carried out especially on animals. A neurogenic atrophy systematically
occurs. In humans, one year after a single injection, the histological recovery
is incomplete. The passive biomechanical analysis of muscle stiffness shows
on the short term, a modulus elastic increase in animals whereas no change
is recorded in humans. 2D US analysis shows gastrocnemius thickness and
pennation angle reduce. MRI volumetry analysis shows muscle atrophy, six
months or one year after a single injection. Sonoelastometry analysis shows,
on the short term, a modulus elastic decrease.
Conclusions.– Very little data exists. The muscle changes need to be taken into
account when seeking functional improvement. The protocols are inconsistent.
2D US and Sonoelastometry should be developed in long term monitoring.
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Background.– Patients with upper motor neuron syndrome often experience
spasticity-related pain due to increased muscle tone and flexor/extensor spasms.
Methods.– A total of 274 post-stroke patients with upper and lower limb spas-
ticity were randomized to OnabotulinumtoxinA (BOTOX®) + standard of care
(SC) or saline + SC in the BOTOX® Economic Spasticity Trial’s double blind
phase. Spasticity-related pain was measured using an 11-point pain numeric
rating scale (0 to 10). Change in pain from baseline and proportion of patients
with ≥ 30% improvement were compared between treatment groups using Wil-
coxon rank-sum and chi2 or Fisher’s exact tests.
Results.– Patient’s mean age was 61 years (SD: 11.4); 41% were female. Of 273
patients that received treatment, 202 experienced baseline spasticity-related pain
with the majority (64%) having pain intensity ≥ 4. Among patients with baseline
pain, the mean change in pain at week 12 among OnabotulinumtoxinA + SC
and saline + SC groups were –1.24 (95% CI: –1.8, –0.7) and –0.31 (–0.9, 0.3),
respectively (P < 0.01). The proportion of patients with ≥ 30% improvement was
51% (37/73) for OnabotulinumtoxinA + SC versus 28% (18/65) for saline + SC
(P < 0.01).
Conclusions.– This is the first large RCT showing statistically significant and
clinically meaningful improvement in spasticity-related pain syndromes from
OnabotulinumtoxinA treatment.
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Background.– BoNT-A depresses recurrent inhibition of lumbar motoneurons
likely due to its retrograde transportation. Because Renshaw cells control group
Ia interneurons mediating reciprocal inhibition between antagonists, we tes-
ted whether this inhibition particularly affected after stroke could recover after
BoNT-A.
Methods.– Effect of posterior tibial nerve stimulation (PTN) on tibialis anterior
electromyogram was investigated in 13 stroke patients during treadmill walking
before and 1 month after BoNT-A injection.
Results.– After injection, the PTN induced reciprocal facilitation in Ia motoneu-
rons during all the swing phase was depressed at the beginning of swing and
reversed into inhibition in midswing.
Spasticity / Annals of Physical and Rehabilitation Medicine 57S (2014) e42–e52 e45
Conclusions.– This suggests that BoNT-A induces spinal plasticity leading to
the recovery of reciprocal inhibition, which is likely to be due to the withdrawal
of inhibitory control from Renshaw cells directly blocked by BoNT-A. This
could help in limiting ankle muscle cocontractions in the transition phase from
stance to swing, to assist dorsiflexion.
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Background.– The therapeutic effects of intramuscular injections of botulinum
toxin type A (BTx) on spasticity can be largely explained by its blocking action
at the neuromuscular junction. BTx is assumed to also have a central action by
affecting the functional organization of the CNS. The aim of the present study is
to assess the action of BTx on spinal motor networks by investigating the post-
activation depression (post-AD) of the soleus H-reflex in post-stroke patients
presenting lower limb spasticity.
Methods.– Soleus H-reflex was investigated in chronic hemiplegic patients
before and 3, 6, 12 weeks after BTx-injections in soleus. H-reflex amplitude
was analyzed in response to electrical stimulation of the tibial nerve at 0.1 Hz
and 0.5 Hz. Post-AD was quantified as the ratio H0.5Hz/H0.1Hz.
Results.– The post-AD was significantly reduced in the affected side compared
to the non-affected side before BTx injection. Three weeks after injection,
the post-AD was reinforced in the paretic leg and significantly higher than in
pre-injection condition.
Conclusions.– BTx-treatment restores the post-AD of soleus H-reflex in post-
stoke paretic patients. As post-AD amount is correlated to the severity of
spasticity, it can be assumed that BTx’s effectiveness in post-stroke rehabilitation
is also due to induced-changes in spinal motor networks.
http://dx.doi.org/10.1016/j.rehab.2014.03.160
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Background.– Compare muscle length, spasticity angle and active range of
motion in adult paretic syndromes due to lesions acquired in infancy vs adult-
acquired lesions.
Methods.– Cross sectional study from a retrospective chart review.
Population.– Convenience sample of 2 groups of clinic patients with spastic
paresis due to an infant lesion (IL, n = 11) or to an adult-acquired lesion (AL,
n = 11).
Evaluation.– Muscle length (XV1), angle of catch (XV3), spasticity angle
(X = XV1–XV3), active range of motion (A) and angle of weakness (XV1–A) in
soleus, gastrocnemius, gluteus maximus, hamstrings, vastus and rectus femoris
muscles at the initial evaluation (pre-toxin).
Results.– The IL group had shorter muscle lengths in gluteus maximus (XV1,
IL, 101 ± 5; AL, 120 ± 5◦; P = 0.02, Mann–Whitney) and hamstrings (XV1, IL,
31 ± 7◦; AL, 63 ± 5◦, P = 0.004), smaller spasticity angles (X, gluteus maxi-
mus, IL, 7 ± 3◦; AL, 15 ± 4◦, P = 0.04; hamstrings, IL, 19 ± 4◦ vs AL, 42 ± 7◦,
P = 0.02) and smaller angle of weakness across all muscles studied (P = 0.04,
Wilcoxon). A was strongly correlated with XV1 across all muscles in the IL group
(P < 0.05) while this was only true for plantar flexors and gluteus maximus in
the AL group.
Conclusions.– Passive mechanical obstacles have greater impact on motor defi-
ciencies in infant paresis than in adult acquired lesions.
http://dx.doi.org/10.1016/j.rehab.2014.03.161
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Background.– The safety profile of onabotulinumtoxinA for treatment of upper
limb spasticity (ULS) was assessed across a range of doses to evaluate treatment
with ≥ 400 U.
Methods.– Integrated data from 18 studies of onabotulinumtoxinA for ULS were
evaluated by 4 dose groups (< 150 U, 150–250 U, 251–399 U, ≥ 400 U). Treat-
ment exposure, incidence of adverse events (AEs), serious AEs, and possible
distant spread of toxin (PDSOT) were assessed, together with the safety profile of
patients who received 4 consecutive onabotulinumtoxinA ≥ 400 U treatments.
Results.– Overall, 1342 patients received ≥ 1 onabotulinumtoxinA treatment;
183 received ≥ 400 U, with 6.6% (88/1330), 12.3% (115/936), 23.3% (113/486),
and 31.2% (96/308) in treatment cycles 1–4, respectively. AE rates were similar
across dose groups, with no consistent increase in incidence of any individual
AE/serious AE and no evidence of PDSOT at doses ≥ 400 U across treatment
cycles. The overall AE rate among the subset of patients (n = 51) with 4 conse-
cutive ≥ 400 U treatments was similar (43.1%, 43.1%, 43.1%, 41.2%), with no
overall change in profile for AEs/serious AEs with increasing treatments.
Conclusions.– OnabotulinumtoxinA at doses ≥ 400 U was well tolerated in ULS
patients, with no consistent pattern of increase in AEs at doses ≥ 400 U, reported
systemic AEs, or change in safety profile over consecutive treatments.
http://dx.doi.org/10.1016/j.rehab.2014.03.162
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Background.– Our study concerns the efficiency of hypnosis during the injections
of botulinum toxin. Hypnosis is widely used in medicine to decrease the anxiety
and the painful felt, but few publications are appeared in physical medicine and
rehabilitation.
Methods.– In this bi-centrique study, the injections are practised at 30 patient’s
spastics. Two groups are constituted: the group “hypnosis” (standards analge-
